Article Text

Download PDFPDF

Lipodystrophy among patients with HIV infection on antiretroviral therapy: a systematic review protocol
  1. Lorena Gomes Cunha Lana1,
  2. Daniela Rezende Garcia Junqueira1,2,3,
  3. Edson Perini1,
  4. Cristiane Menezes de Pádua1
  1. 1Departamento de Farmácia Social, Faculdade de Farmácia, Centro de Estudos do Medicamento (Cemed), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
  2. 2Faculty of Health Sciences, The University of Sydney, Sydney, Australia
  3. 3Programa de Pós-graduação em Ciências Farmacêuticas, Universidade de Sorocaba-Uniso, Sorocaba, São Paulo, Brazil
  1. Correspondence to Professor Cristiane Menezes de Pádua; campadua{at}farmacia.ufmg.br

Abstract

Introduction Lipodystrophy is a frequent and disfiguring adverse effect of antiretroviral therapy (ART) in patients with HIV. It affects the quality of life of the patient and adherence to treatment, and generates new needs for comprehensive healthcare services. The aim of this study will be to conduct a systematic review of the literature from observational studies and describe lipodystrophy among patients with HIV infection during current or previous use of ART.

Methods and analysis A systematic review of observational studies published in MEDLINE, CINAHL, LILACS, EMBASE and International Pharmaceutical Abstracts will be carried out. Citations of included studies will be checked to identify additional studies not identified in the electronic searches. It will include any observational study that considered lipodystrophy as the primary or secondary outcome and that had enrolled adolescent and adult patients with HIV infection who were on current or previous ART for at least 6 months. Data extraction and analysis will be performed independently by two reviewers. The extracted data will be discussed, decisions documented and, where necessary, the authors of the studies will be contacted for clarification. Measures of frequency, prevalence and incidence of lipodystrophy will be stratified according to definition, method of diagnosis and risk factors of the outcome.

Ethics and dissemination Ethics is not required given this is a protocol for a systematic review. The findings of this study will be widely disseminated through peer-reviewed publications and conference presentations. Updates of the review will be conducted to inform and guide healthcare practice.

Protocol registration PROSPERO—42013005450.

  • lipodystrophy
  • antiretroviral regimen
  • HIV
  • adverse drug reaction
  • systematic review

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.